In short
MRNA3771 is an investigational medicine being studied for chronic hepatitis B. The clinical trial data includes one Phase 1/2 study that was suspended, with a planned enrollment of 66 participants. The trial aimed to assess the safety, tolerability, and early efficacy of the substance given by intravenous infusion.
Key points
- MRNA3771 is an investigational substance studied in chronic hepatitis B.
- The only registered trial is a Phase 1/2 study with a planned enrollment of 66 participants.
- The trial status is suspended, meaning the study is not currently recruiting or treating participants.
- The medicine was given by intravenous infusion in the trial.
- The primary outcome measured safety and tolerability, specifically treatment-emergent adverse events up to Month 6.
- The trial also planned to look at pharmacokinetics, pharmacodynamics, and efficacy.
What is MRNA3771?
MRNA3771 is an investigational medicine that has not received marketing authorisation in these records. The available trial data refers to the substance under the study name CRMA-1001, which is the name used in the registered clinical trial. No trade names or other development codes are provided in the registry data. Because the substance is still being studied, its full profile as a medicine is not yet established.
How does MRNA3771 work?
The registry data provided does not describe the mechanism of action of MRNA3771. The trial record states that the study aimed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy in chronic hepatitis B, but no molecular target or pathway is specified. Without supplementary sources, the exact way MRNA3771 might act against the hepatitis B virus cannot be described on this page.
Which conditions is MRNA3771 studied for?
The only condition for which MRNA3771 is registered in the available trial data is:
- Chronic hepatitis B — a long-term infection of the liver caused by the hepatitis B virus, which can lead to liver damage, cirrhosis, or liver cancer over time.
How is MRNA3771 given?
In the registered trial, MRNA3771 (under the name CRMA-1001) was administered by intravenous infusion. No pharmaceutical form other than the intravenous infusion is mentioned in the available data. The trial planned to evaluate both single and multiple doses of the substance.
What do the clinical trials show?
There is one registered clinical trial for MRNA3771 in the provided data. It is a Phase 1/2 study that was designed to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of the substance in people with chronic hepatitis B. The trial had a planned enrollment of 66 participants.
The status of the trial is suspended, meaning that the study is not currently active and is not recruiting or treating participants. The primary outcome measure was the incidence and severity of treatment-emergent adverse events (TEAEs) from baseline to Month 6. Treatment-emergent adverse events are side effects that appear or worsen after treatment begins. The trial also planned to assess pharmacokinetics (how the body absorbs, distributes, metabolises, and eliminates the medicine), pharmacodynamics (the effects of the medicine on the body), and efficacy.
Because the trial is suspended and no results are reported in the registry data, no conclusions about the safety or effectiveness of MRNA3771 can be drawn at this time.
What side effects are known?
The available registry data does not report any side effects for MRNA3771. The trial was designed to measure the incidence and severity of treatment-emergent adverse events, but no results are provided in the data. Therefore, no side effect profile can be described on this page.